Studies reporting switch between anti-IL-1 treatments
| Study | Treatment switch | Patient | N | Reasons for switching |
|---|---|---|---|---|
| Eroglu et al 201636 | Anakinra to canakinumab | CAPS | 3 | Local reactions at injection site (n=2); pain at injection site and non-compliance (n=1) |
| Parker et al 201645 | Anakinra to canakinumab | CAPS | 13 | Due to canakinumab availability |
| Houx et al 201538 | Anakinra to canakinumab | CAPS | 48 | Personal convenience |
| Anton et al 201534 | Anakinra to canakinumab | CAPS | 5 | More convenient administration (n=4); severe local reactions to anakinra (n=1) |
| Rossi-Semerano et al 201586 | Anakinra to canakinumab | CAPS | 3 | Inefficacy or loss of efficacy, AE, persistent remission, or patient request |
| Russo et al 201465 | Anakinra to canakinumab | CAPS | 5 | Inadequate control of disease activity (n=5); poor compliance with daily injection of anakinra (n=3); patien/parent preference (n=2) |
| Kuemmerle-Deschner et al 201359 | Anakinra to canakinumab | CAPS (MWS) | 10 | Treatment failure (n=3); patient/parent preference (n=7) |
| Wittkowski et al 201167 | Anakinra to canakinumab | CAPS | 10 | Lack of efficacy or parent preference (n=10) |
| Kuemmerle-Deschner et al 201157 | Anakinra to canakinumab | CAPS (MWS) | 6 | Inconvenience of daily injection and secondary treatment failure (n=6) |
| Kone-Paut et al 201739 | Canakinumab to anakinra | CAPS (CINCA/NOMID) | 1 | Reason not reported |
| Parker et al 201645 | Canakinumab to anakinra | CAPS | 5 | One patient was initially treated with canakinumab but changed to anakinra during pregnancy, and then restarted canakinumab following a successful pregnancy. Incomplete response (n=3); for better response (n=1) |
| Lane et al 201541 | Canakinumab to anakinra | CAPS (CINCA/NOMID and MWS) | 2 | AEs |
| Ter Haar et al 201693 | Anakinra to canakinumab | HIDS/MKD | 2 | Inadequate efficacy (n=2) |
| Rossi-Semerano et al 201586 | Anakinra to canakinumab | HIDS/MKD | 4 | Inefficacy or loss of efficacy, AE or patient request |
| Galeotti et al 201278 | Anakinra to canakinumab | HIDS/MKD | 4 | More convenient dosing schedule and to avoid injection site reaction (n=4) |
N is the total number of patients who were switched from one treatment to another. n is the number of patients who reported the particular reason for switching.
AEs, adverse events; CAPS, cryopyrin-associated periodic syndromes; CINCA, chronic infantile neurological cutaneous and articular syndrome; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; MWS, Muckle–Wells syndrome; NOMID, neonatal-onset multisystem inflammatory disease.